Moreover, the role of CD200 in immune evasion and treatment resistance in pancreatic cancer hints at its potential effects as a biomarker for analogous therapeutic strategies in breast cancer, covering pre- and post-surgery interventions [84]. The gene discussed is CD200; the disease is familial pancreatic carcinoma.